This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): somatropin
Description: Nutropin, Nutropin AQ, Nutropin Depot, and Protropin are Genentech’s four recombinant human growth hormone/somatropin formulations indicated for the treatment of short stature.
Protropin, approved in 1985, was the first recombinant growth hormone to reach the market, filling a gap left when it was determined that GH harvested from cadavers carried a risk of Creutzfeldt-Jakob disease. The newer Nutropin formulations removed the initial amino acid to make the protein more similar to natural GH. Protropin has activity similar to Nutropin, and has retained its indication for children with innate GH deficiency.
Deal Structure: Nutropin was originally developed by Genentech.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Pink Sheet Nutropin Depot FDA Reviewers
Pink Sheet Nutropin Depot Clinical Development
Pink Sheet In Brief: Genentech Nutropin AQ
Additional information available to subscribers only: